Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Trial
Official title:
Facebook Intervention for Young Onset Melanoma Patients and Families
Verified date | January 2024 |
Source | Rutgers, The State University of New Jersey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention works in improving skin examination in participants with melanoma and their families. Young Melanoma Family Facebook intervention or Healthy Lifestyle Facebook intervention may help improve total cutaneous examinations, skin self-examinations, and sun protection among first degree relatives of young onset participants and the participants themselves.
Status | Recruiting |
Enrollment | 1160 |
Est. completion date | December 1, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - PATIENT: Diagnosed with stage 0-3 melanoma in the last 5 years - PATIENT: Age at diagnosis 18-39 years - PATIENT: Completed treatment at least 3 months previously - PATIENT: Recruited from New Jersey or California State Cancer Registry or MD Anderson Cancer Center - PATIENT: Does not have a concurrent cancer diagnosis - PATIENT: Able to speak and read English - PATIENT: Access to computer, internet, and has a Facebook account - PATIENT: At least one family member consents - FDR: Current age 18-80 years - FDR: Does not have a personal history of melanoma - FDR: Able to speak and read English - FDR: Access to computer, internet, and has a Facebook account - FDR: Has only one FDR with melanoma (patient) - FDR: Has not had a total cutaneous examination (TCE) in the past 3 years, has done skin self-exam (SSE) fewer than three times in the past year, OR has a sun protection habits average score less than or equal to 4 (?often?) - FDR: Patient consents Exclusion Criteria: - Physical Activity Readiness Questionnaire (Thomas, et. al., 1992): This 7-item scale will be used to screen out individuals who will need to consult a physician for medical clearance before engaging in physical activity. If a participant checks off any of the items, the investigators will ask for a physician clearance before consenting to study |
Country | Name | City | State |
---|---|---|---|
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Rutgers, The State University of New Jersey | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mediator analyses - Intervention Group | Mediator analyses examining normative influences on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - (Relatives) | Mediator analyses examining family and peer support and discussion on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - Intervention Group - Risks | Mediator analyses examining risk on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - Intervention Group - Benefits | Mediator analyses examining benefits on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - Intervention Group - Barriers | Mediator analyses examining barriers on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - Intervention Group - Self-efficacy | Mediator analyses examining self-efficacy on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Mediator analyses - Intervention Group - Change Strategies | Mediator analyses examining use of change strategies on the effects of intervention group on TCE, SSE and sun protection. | 6 months | |
Other | Moderator analysis - Melanoma Risk Factors | Moderator analysis Melanoma risk factors will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Moderator analysis - month of the year enrolled | Moderator analysis month of the year enrolled will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Moderator analysis - Residential Latitude | Moderator analysis residential latitude will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Moderator analysis - Sex | Moderator analysis sex will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Moderator analysis - patient disease stage | Moderator analysis patient disease stage will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Moderator analysis relationship to patient | Moderator analysis relationship to patient will explore whether the intervention group is more effective for subsets of FDRs. | 6 months | |
Other | Predictor - Engagement | Facebook engagement including likes, comments- collected at the end of the group | 6 months | |
Other | Predictor - Social Network Use | Social network use measured by self-reported frequency of use of popular social media sites | 6 months | |
Primary | Total cutaneous examination (TCE) | Will be assessed as a binary response (yes/no) did participant have one | At 6 months | |
Secondary | Skin Self-exam (Relatives) | Skin self-exam of first degree relatives will be analyzed as a binary (yes/no) Response did participant complete one Yes/No | Up to 5 years | |
Secondary | Skin self-exam - Count Response (Relatives) | Skin self exam of first degree relatives count response will be calculated as frequency/month. Frequency per month reported as a number. | Up to 5 years | |
Secondary | Skin self-exam - Comprehensiveness (Relatives) | : Skin self-exam of first degree relatives comprehensiveness calculated as total # body parts examined during the skin self-exam | Up to 5 years | |
Secondary | Sun Protection Habits (Relatives) | sun protection habits score of first degree relatives will be calculated as continuous variables using the Sun protection behaviors scale (Glanz, et. al., 2002) which measures 5 behaviors (regular outdoor use of: sunscreen, hat, shade, long-sleeved shirt, sunglasses). | Up to 5 years | |
Secondary | Skin self-exam - Count Response (Patients) | Skin self-exam of patients count response calculated as (frequency/month). Frequency per month reported as a number | Up to 5 years | |
Secondary | Skin self-exam - Comprehensiveness (Patients) | Skin self-exam of patients comprehensiveness calculated as total # body parts examined during the skin self-exam. | Up to 5 years | |
Secondary | Sun Protection Habits (Patients) | sun protection habits score of patients will be calculated as continuous variables using the Sun protection behaviors scale (Glanz, et. al., 2002) which measures 5 behaviors (regular outdoor use of: sunscreen, hat, shade, long-sleeved shirt, sunglasses). | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039801 -
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT04940299 -
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT04990726 -
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
|
||
Active, not recruiting |
NCT04967196 -
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT03554083 -
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
|
Phase 2 | |
Recruiting |
NCT04593277 -
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
|
N/A | |
Active, not recruiting |
NCT03033576 -
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
|
Phase 2 | |
Suspended |
NCT04708418 -
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy in Patients With Operable Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03816332 -
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
|
Phase 1 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Recruiting |
NCT04314401 -
National Cancer Institute "Cancer Moonshot Biobank"
|
||
Active, not recruiting |
NCT02506153 -
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
|
Phase 3 | |
Recruiting |
NCT05764395 -
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
|
Phase 2 | |
Active, not recruiting |
NCT04516122 -
Bone Loss in Melanoma Survivors Receiving Immunotherapy
|
||
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01989585 -
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
Recruiting |
NCT05098210 -
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
|
Phase 1 | |
Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 |